Aodong, Jilin (000623): The main pharmaceutical industry continues to strengthen finance to empower established pharmaceutical companies to usher in new development
Aodong, Jilin (000623): Extending employee shareholding time and continuously increasing management enthusiasm
Aodong, Jilin (000623): Anshen Brain Supplement Leading Brand Medicine, Finance, and Health Multi-wheel Drive Development
Aodong, Jilin (000623): The future development of “pharmaceutical+finance+big health” multi-wheel drive companies can be expected
Aodong, Jilin (000623): Combining offense and defense, the main pharmaceutical industry is expected to be revalued
Jilin Aodong (000623) Company In-depth Report: “Pharmaceutical+Big Health+Finance” Drives “Jilin Time-honored Brand” Steady and Long-Term
[Northeast Securities] Jilin Aodong Quarterly Report Review: Investment Income Contributes to Performance Flexibility
[Northeast Securities] Aodong, Jilin: Benefiting from the bull market environment, investment returns have increased dramatically
[Cathay Pacific Junan Securities] Aodong, Jilin: The performance of participating in GF Securities increased dramatically
[Guotai Junan Securities] Jilin Aodong: the main pharmaceutical industry and securities investment ushered in a revaluation
[Everbright Securities] Jilin Aodong: a pharmaceutical pearl with both offensive and defensive and undervalued value
[Huachuang Securities] Jilin Aodong: pharmaceutical industry profit release accelerated, undervalued
[northeast Securities] comments on the third quarterly report of Aodong, Jilin: the development potential of the main pharmaceutical industry is great, and the exclusive products are worthy of attention.
Jilin Aodong (000623) Research report: the potential of the main pharmaceutical industry is being tapped.
[Guohai Securities] Jilin Aodong: the potential of the main pharmaceutical industry is being tapped.
[Tianxiang Investment] Aodong, Jilin: GF Securities Co., LTD. 's one-time additional offering greatly increased his net profit.
[Huatai United Securities] Jilin Aodong's comment on suspending additional investment in artificial liver projects: There are many good things, and approval still needs to be waited
[Tianxiang Investment] Aodong, Jilin: Investment income increases net profit, and the main pharmaceutical business stabilizes
[Cathay Pacific Junan Securities] Aodong, Jilin: Main business is steadily improving, and non-recurring profit and loss drive growth
[Qunyi Securities (Hong Kong)] Aodong, Jilin: The main pharmaceutical industry is developing steadily, and profit prospects for artificial liver and iron ore boosts valuation
No Data